Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.

Journal of cardiology - 1 Mar 2013

Nishiwaki Masato, Ikewaki Katsunori, Ayaori Makoto, Mizuno Kyoichi, Ohashi Yasuo, Ohsuzu Fumitaka, Ishikawa Toshitsugu, Nakamura Haruo

Abstract excerpt

BACKGROUND: The beneficial effect of statins for cardiovascular disease (CVD) prevention has been well established. However, the effectiveness among different phenotypes of dyslipidemia has not been confirmed. OBJECTIVE: We evaluated the effect of pravastatin on the incidence of CVD in relation to the phenotype of dyslipidemia. METHODS: The MEGA Study evaluated the effect of low-dose pravastatin on primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Cholesterol, HDL

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dyslipidemias

Share to Electrophoresis

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Pravastatin

Share to Randomized Controlled Trials as Topic

Share to Risk Reduction Behavior

Source

Identifiers

PMID: 23265677
DOI: 10.1016/j.jjcc.2012.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.PMID 23265677Read ↗

LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial.Semantic proximity Read ↗

Primary and Secondary Effects of Statin on Cerebro-Cardiovascular Disease Using the Nationwide Health Screening DataSemantic proximity Read ↗

Prevalence and association with diabetes and obesity of lipid phenotypes among the hypertensive Chinese rural adults.Semantic proximity Read ↗

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.Semantic proximity Read ↗

Association of High-Density Lipoprotein Cholesterol Phenotypes with the Risk of Cardiovascular Diseases and Mortality: A Cohort Study in Korea.Semantic proximity Read ↗

Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study.Semantic proximity Read ↗

Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy.Semantic proximity Read ↗

Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.Semantic proximity Read ↗

Atherogenic lipid phenotype in a general group of subjects.Semantic proximity Read ↗

Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.Semantic proximity Read ↗

The human paraoxonase-1 phenotype modifies the effect of statins on paraoxonase activity and lipid parameters.Semantic proximity Read ↗

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.